Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Enterprise Value data on file, last reported at -$376.0 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 25.36% year-over-year to -$376.0 million in Q1 2026; TTM through Mar 2026 was -$376.0 million, a 25.36% increase from a year earlier, with the FY2025 full-year figure at -$449.9 million, up 25.21% from the prior year.
• Enterprise Value for Q1 2026 stood at -$376.0 million, up from -$449.9 million in the prior quarter.
• Over the last five years, Enterprise Value for NTLA reached as high as -$376.0 million in Q1 2026 and fell as low as -$933.5 million in Q1 2023.
• Historically, Enterprise Value has averaged -$690.0 million across 5 years, with a median of -$691.1 million in 2024.
• Across the five-year window, Enterprise Value plunged 65.26% in 2022 and surged 36.34% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$681.1 million in 2022, then tumbled by 33.94% to -$912.2 million in 2023, then surged by 34.06% to -$601.5 million in 2024, then rose by 25.21% to -$449.9 million in 2025, then gained by 16.43% to -$376.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$376.0 million in Q1 2026, -$449.9 million in Q4 2025, and -$511.0 million in Q3 2025.